Federated Hermes Inc. Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Federated Hermes Inc. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 137,141 shares of the biopharmaceutical company’s stock, valued at approximately $26,250,000.

A number of other large investors have also recently bought and sold shares of the company. Daiwa Securities Group Inc. grew its stake in Alnylam Pharmaceuticals by 3.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 10,805 shares of the biopharmaceutical company’s stock worth $2,068,000 after buying an additional 400 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Alnylam Pharmaceuticals by 99.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 45,080 shares of the biopharmaceutical company’s stock worth $8,629,000 after buying an additional 22,473 shares in the last quarter. Vontobel Holding Ltd. lifted its holdings in shares of Alnylam Pharmaceuticals by 88.6% in the fourth quarter. Vontobel Holding Ltd. now owns 10,875 shares of the biopharmaceutical company’s stock worth $2,082,000 after acquiring an additional 5,109 shares during the last quarter. Aquila Investment Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 50.0% in the fourth quarter. Aquila Investment Management LLC now owns 3,000 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Simplicity Solutions LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 23.1% in the fourth quarter. Simplicity Solutions LLC now owns 1,997 shares of the biopharmaceutical company’s stock worth $382,000 after acquiring an additional 375 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Down 0.5 %

NASDAQ ALNY opened at $144.41 on Monday. The company has a fifty day simple moving average of $151.56 and a 200 day simple moving average of $166.73. Alnylam Pharmaceuticals, Inc. has a 12-month low of $143.50 and a 12-month high of $218.88. The company has a market cap of $18.19 billion, a P/E ratio of -40.56 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. During the same period in the previous year, the business posted ($1.68) EPS. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current year.

Analysts Set New Price Targets

ALNY has been the subject of a number of research reports. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $230.00 to $173.00 in a report on Friday, February 16th. Wells Fargo & Company dropped their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 13th. Nine research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $216.12.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.